Subscribe

Shitanshu Uppal

KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival and OS compared to chemoradiotherapy alone

CALLA: Durvalumab versus Placebo with Chemoradiotherapy for Locally Advanced Cervical Cancer

Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer

SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer

Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile

GOG 249: Vaginal Brachytherapy Plus Chemotherapy vs Pelvic Radiation in High-Risk Early-Stage Endometrial Cancer

The study did not demonstrate superiority or equivalence due to similar outcomes in both arms. The higher incidence of pelvic/para-aortic nodal failures in the VCB/C arm suggests the importance of pelvic RT in preventing regional recurrences.

KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.

GOG 252: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma

The duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab, and was better tolerated than IP cisplatin.

ICON8: Weekly Dose-Dense Chemotherapy in First-Line Epithelial Ovarian Cancer (Primary PFS Analysis)

Weekly dose-dense chemotherapy does not significantly improve progression-free survival compared to standard 3-weekly chemotherapy in a predominantly European population.

PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Niraparib significantly extends progression-free survival among patients with newly diagnosed advanced ovarian cancer post-response to platinum-based chemotherapy, regardless of homologous-recombination deficiency status.

Publications Update # 50

GYOEDU updates, women's leadership programs, SHAPE trial, CONCERV and bowel surgery - staplers

SHAPE: Simple vs. Radical Hysterectomy for Low-Risk Early-Stage Cervical Cancer

Simple hysterectomy is not inferior to radical hysterectomy in terms of the 3-year incidence of pelvic recurrence and presents a lower risk of urinary complications.